backNovo Nordisk, the Danish pharmaceutical company behind Ozempic and Wegovy, is pausing hiring in what it considers non essential areas, according to Reuters. The move signals a more cautious stance after a period of rapid growth driven by its obesity treatments, which have attracted global attention.
The company now faces a tougher competitive landscape, with rivals advancing, lower priced options emerging, and a decline in market value. These pressures call into question its ability to sustain recent expansion and are leading Novo Nordisk to tighten priorities and costs while it reassesses its medium term strategy.
*
share
